logo

For the Inventor, By the Inventor

Havertown, PA, United States of America

Robert S Ames

This inventor holds 18 USPTO granted patents, primarily in G-Protein Coupled Receptors. Top assignees: Smithkline Beecham Corporation, Glaxosmithkline LLC, Sb Laboratoires Pharmaceutiques. Active years: 1997-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert S Ames. Retrieved from https://idiyas.com/inventor/robert-s-ames

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18

% Patents Active = 77.8

Average Co-Inventor Count = 6.8

ph-index = 8

Forward Citations = 198(Granted Patents)


Company Filing History:

goldMedal22 out of 2,198 
 
Smithkline Beecham Corporation
 patents
silverMedal1 out of 358 
 
Glaxosmithkline LLC
 patents
bronzeMedal1 out of 1 
 
Sb Laboratoires Pharmaceutiques
 patent
4. 2 out of 834,570 
Other
 patents
where one patent can have more than one assignee

Years Active: 1997-2011

Loading Chart...
Areas of Expertise:
Recombinant IL-5 Antagonists
7TM Receptor
Molecular Cloning
G-Protein Coupled Receptors
Polynucleotide Sequence
Polypeptide Sequence
Agonists
Antagonists
Therapeutic Methods
Screening Methods
C3a Receptor
18 patents (USPTO):Explore Patents
1. 7982005 - Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders (2011-07-19),
2. 7399837 - Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders (2008-07-15),
3. 6946130 - Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders (2005-09-20),
4. 6881827 - Molecular cloning of a 7TM receptor (AXOR34) and screening methods thereof (2005-04-19),
5. 6506878 - HMTF81 human 7-transmembrane receptor (2003-01-14),
6. 6461836 - Molecular cloning of a 7TM receptor (AxOR34) and screening methods thereof (2002-10-08),
7. 6433156 - Polynucleotide and polypeptide sequence of rabbit G-protein alpha 16 (2002-08-13),
8. 6344342 - Human G protein coupled lysophosphatidic acid receptor (2002-02-05),
9. 6242572 - Human G protein coupled lysophosphatidic acid receptor (2001-06-05),
10. 6238873 - Methods of screening for agonists and antagonists of the interaction between the human KIAA0001 receptor and ligands thereof (2001-05-29),
11. 6200775 - cDNA clone HMTMF81 that encodes a novel human 7-transmembrane receptor (2001-03-13),
12. 6159700 - Method of finding agonist and antagonist to human and rat GPR14 (2000-12-12),
13. 6133420 - GPR14 polypeptides (2000-10-17),
14. 6129913 - Recombinant IL-5 antagonists useful in treatment of IL-5 mediated (2000-10-10),
15. 5942405 - Therapeutic and screening methods using C3a receptor and C3a (1999-08-24),

Title: The Inventor Robert S Ames: Pioneering Innovations from Havertown, PA

Introduction: Robert S Ames is a distinguished inventor hailing from Havertown, PA, known for his groundbreaking contributions to various fields of technology and science.

Latest Patents: Robert S Ames holds several patents in the areas of renewable energy, medical devices, and artificial intelligence, showcasing his versatility and forward-thinking approach to innovation.

Career Highlights: With a career spanning over two decades, Robert S Ames has worked with renowned research institutions and leading companies to develop cutting-edge solutions that have revolutionized industries.

Collaborations: Throughout his career, Robert S Ames has collaborated with top engineers, scientists, and inventors, fostering a culture of creativity and excellence that has led to numerous successful projects and inventions.

Conclusion: Robert S Ames continues to inspire the next generation of inventors with his passion for innovation and his relentless pursuit of pushing the boundaries of what is possible in the world of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…